Melanoma News and Research

Latest Melanoma News and Research

Array BioPharma third quarter revenue increases to $19.1M

Array BioPharma Inc. today reported financial results for the third quarter of fiscal 2012.

2 May 2012

AlderMed enters distribution agreement with Gulmay Medical for Xstrahl-100 therapy system

AlderMed announced today it has entered into a three-year exclusive distribution agreement with Gulmay Medical, manufacturer of the Xstrahl-100 therapy system.

From Xstrahl 30 Apr 2012

Mount Sinai experts to share skin cancer prevention tips on May 7

Skin cancer is the most common form of cancer in the United States, with one in five Americans developing it over the course of their lives. It's also one of the most preventable types of cancers. Since May is Skin Cancer Awareness Month and Melanoma Monday is May 7, Mount Sinai experts are sharing tips on prevention and insight on the new FDA labeling requirements on sunscreen.

30 Apr 2012

Researchers use Moffitt's Total Cancer Care to create designer lymph nodes

Researchers at Moffitt Cancer Center are in the first phase of creating "designer lymph nodes." Designer lymph nodes are built with specialized gene-modified cells that are injected into patients and produce a pre-planned immunologic response for cancer patients locally and then throughout their bodies. The researchers are examining a cancer vaccine "boosting" effect of the manufactured lymph nodes in patients with advanced melanoma.

30 Apr 2012

A melanoma cloaking protein

Johns Hopkins and Yale scientists have found that melanoma cells use a cloaking protein to hide from immune cells poised to attack the cancer. Nearly 40 percent of their sampling of melanoma tissues contained the B7-H1 protein, also called PD-L1, and scientists say it could be used as a target for new therapies.

26 Apr 2012

Melanomas express B7-H1 protein to hide from T-cells

26 Apr 2012

MMP-10 gene plays a dual role in lung cancer

A single gene that promotes initial development of the most common form of lung cancer and its lethal metastases has been identified by researchers at Mayo Clinic in Florida.

25 Apr 2012

Cancer therapy with common cold virus

Common viruses have become the latest weapon against cancer. There is the case of the eight-year-old African boy diagnosed with Burkitt's lymphoma at a Ugandan health clinic. He was exposed to the measles virus and in the next few weeks his tumour regressed completely and he entered remission. But only relatively recently have scientists clinically examined the interaction between viruses and cancers in the growing area of oncolytic virotherapy.

24 Apr 2012

Loyola dermatologists to offer free melanoma screenings in May

Dermatologists from Loyola University Health System will offer free skin cancer screenings in May as part of Skin Cancer Detection and Prevention Month.

24 Apr 2012

Delcath closes $20M credit facility

Delcath Systems, Inc. today announced it has closed a $20 million working capital line of credit revolver with Silicon Valley Bank, a leading provider of banking services in the life sciences. The credit facility is available for general corporate purposes supporting the overall growth and development of the Company.

23 Apr 2012

Health Discovery launches MelApp for melanoma risk assessment

Health Discovery Corporation, the molecular diagnostics company that launched MelApp, the first SVM-based image analysis iPhone app for melanoma risk assessment is featured in this month's Men's Health Magazine.

21 Apr 2012

Immunotherapy may also help elderly cancer patients

Cancer is much more likely in the elderly than the young, and their bodies often are less prepared to fight the disease and the often-toxic side effects of treatment.

16 Apr 2012

RiboMed releases multi-marker methylation prognostic test for glioma

RiboMed Clinical Services Laboratory (RCSL), a CLIA-certified subsidiary of RiboMed Biotechnologies, today announced the release of a multi-marker methylation prognostic test for grading gliomas, the most common type of brain cancer.

12 Apr 2012

Delcath, NKI-AVL enter initial launch and training agreement for CHEMOSAT system

Delcath Systems, Inc. announced today that the Company has entered into an initial launch and training agreement with the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AVL) in Amsterdam, The Netherlands.

10 Apr 2012

Provectus announces data from PV-10 Phase 2 study on metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 study of PV-10 for metastatic melanoma will be presented at the HemOnc Today - Melanoma and Cutaneous Malignancies Conference on April 13, 2012.

10 Apr 2012

Delcath’s second generation CHEMOSAT system receives European CE Mark

Delcath Systems, Inc. today announced that the Company has received CE Mark approval for the second generation hemofiltration cartridge of the Company's proprietary Hepatic CHEMOSAT Delivery System.

6 Apr 2012

Positive preclinical results from Cancer Therapeutics' CTX-0294945 plus Avastin study

Cancer Therapeutics, a company focused on translating cancer biology research into novel treatments for cancer, today announced positive preclinical results for CTX-0294945 as an adjuvant therapy to the cancer drug Avastin (bevacizumab - Genentech/Roche). The data is presented today in a late breaking poster at the American Association for Cancer Research (AACR) Annual Meeting 2012 in Chicago, USA.

4 Apr 2012

Navidea announces FDA extension of Lymphoseek PDUFA date by three months

Navidea Biopharmaceuticals, Inc. today announced that yesterday it received notification from the United States Food and Drug Administration (FDA) that the Prescription Drug User Fee Act (PDUFA) date for 99m-Tc-Tilmanocept, has been modified to September 10, 2012, a 90-day extension from the initial PDUFA date of June 10th.

4 Apr 2012

Combination treatment effective against melanoma

Research from The Cancer Institute of New Jersey (CINJ) shows that a coordinated effort to block signaling pathways that promote cancer cell growth and survival enhances programmed cell death in melanoma.

3 Apr 2012

Transgenic mice to visualize metastasis and inflammation

One of the major routes of tumor cell dissemination to form metastasis at distant organs in the body is the lymphatic system. To study this process, still poorly understood, and to gain information on which tumors prefer this route for dissemination and how to block it, researchers of the Spanish National Cancer Research Center, led by researcher Sagrario Ortega, have created transgenic mice in which, for the first time, the growth of the lymphatic vessels can be visualized in the whole animal, by a light-emitting reaction, as tumor progresses and forms metastasis.

3 Apr 2012